Comparison of the cyclophosphamide, methotrexate, cytarabine, and ifosfamide doses, and IT prophylaxis in reported treatment regimens for adult BL
Reference . | Protocol . | Duration, no. of cycles . | Cyclophosphamide, mg/m2* . | Methotrexate, mg/m2* . | Cytarabine, mg/m2* . | Ifosfamide, mg/m2* . | IT prophylaxis . |
|---|---|---|---|---|---|---|---|
| Bernstein et al58 | Stanford | 6-9 | 1200 | 3000 | None | None | IT MTX |
| Lopez et al59 | MD Anderson 81-01 | 15 | 1000 × 1 dose | 1000 | 20 q 8 h × 15 doses | 1000 × 5 doses | IT MTX, ARA-C, and HC |
| MD Anderson 84-30 | 9 | 1000 × 1 dose | 1000 | 500 × 1 dose and 20 q 8 h × 15 doses | None | IT MTX, ARA-C and HC | |
| McMaster et al10 | Vanderbilt | 2 | 1500 × 2 doses | 200 | None | None | Given at investigator's discretion |
| Longo et al60 | ProMACE-MOPP | 6-9 | 500-650 × 1-2 doses | 500-3000 | None | None | CNS XRT if BM positive |
| ProMACE-Cytabom | 6 | 650 × 1 dose | 120 | 300 | None | CNS XRT if BM positive | |
| Divine et al61 | ACVBP | 8 | 1200 | 3000 as maintenance for patients with a CR only | For patients in CR only | For patients in CR only | IT MTX and HC |
| Soussain et al11 | LMB 81, 84, 86, and 89 | 4-7† | Cytoreduction: 300 × 1 dose | Cytoreduction: None | Cytoreduction: None | Cytoreduction: None | IT MTX, ARA-C, and HC (CNS XRT only if + CNS disease) |
| Induction: 500-1000 × 3 doses | Induction: 3000-8000 | Induction: None | Induction: None | ||||
| Consolidation: None | Consolidation: 3000 | Consolidation: 100-3000 × 4-5 doses | Consolidation: None | ||||
| Hoelzer et al55 | B-NHL 83 | 6 | Cytoreduction: 200 × 5 doses | Cytoreduction: none | Cytoreduction: none | Cytoreduction: none | |
| Treatment: 200 × 5 doses | Treatment: 500 | Treatment: 300 | CNS XRT, IT MTX (spinal XRT if + CNS disease) | ||||
| B-NHL 86 | 6 | Cytoreduction: 200 × 5 doses | Cytoreduction: none | Cytoreduction: none | Cytoreduction: none | ||
| Treatment: 200 × 5 doses | Treatment: 1500 | Treatment: 150 q 12 h × 8 doses | Treatment: 800 × 5 doses | CNS XRT, IT MTX, ARA-C, and DEX (spinal XRT if + CNS disease) | |||
| Todeschini et al63 | Modified POG 8617 | 6 | 300 q 12 h × 6 doses | 1000 | 3000 q 12 h × 4 doses | None | IT MTX and ARA-C |
| Magrath et al54,64 | CODOX-M/IVAC | Low risk: 3 CODOX-M | 800 × 1 dose and 200 × 4 doses | 6720 | None | None | IT MTX & ARA-C (CNS XRT only if + CNS disease) |
| High risk: 4 CODOX-M/IVAC | 800 × 1 dose and 200 × 4 doses | 6720 | 2000 q 12 h × 4 doses | 1500 × 5 doses | IT MTX & ARA-C (CNS XRT only if + CNS disease) | ||
| Thomas et al56 | Hyper-CVAD | 8 | 300 q 12 h × 6 doses for 4 cycles | 1000 for 4 cycles | 3000 q 12 h × 4 doses for 4 cycles | None | IT MTX and ARA-C (CNS XRT only if + CNS disease) |
| Lee et al67 | CALGB 9251 | 6 | Cytoreduction: 200 × 5 doses | 1500 | 150 × 2 doses | 800 × 5 doses | IT MTX, ARA-C, HC, and CNS XRT |
| Treatment: 200 × 5 doses |
Reference . | Protocol . | Duration, no. of cycles . | Cyclophosphamide, mg/m2* . | Methotrexate, mg/m2* . | Cytarabine, mg/m2* . | Ifosfamide, mg/m2* . | IT prophylaxis . |
|---|---|---|---|---|---|---|---|
| Bernstein et al58 | Stanford | 6-9 | 1200 | 3000 | None | None | IT MTX |
| Lopez et al59 | MD Anderson 81-01 | 15 | 1000 × 1 dose | 1000 | 20 q 8 h × 15 doses | 1000 × 5 doses | IT MTX, ARA-C, and HC |
| MD Anderson 84-30 | 9 | 1000 × 1 dose | 1000 | 500 × 1 dose and 20 q 8 h × 15 doses | None | IT MTX, ARA-C and HC | |
| McMaster et al10 | Vanderbilt | 2 | 1500 × 2 doses | 200 | None | None | Given at investigator's discretion |
| Longo et al60 | ProMACE-MOPP | 6-9 | 500-650 × 1-2 doses | 500-3000 | None | None | CNS XRT if BM positive |
| ProMACE-Cytabom | 6 | 650 × 1 dose | 120 | 300 | None | CNS XRT if BM positive | |
| Divine et al61 | ACVBP | 8 | 1200 | 3000 as maintenance for patients with a CR only | For patients in CR only | For patients in CR only | IT MTX and HC |
| Soussain et al11 | LMB 81, 84, 86, and 89 | 4-7† | Cytoreduction: 300 × 1 dose | Cytoreduction: None | Cytoreduction: None | Cytoreduction: None | IT MTX, ARA-C, and HC (CNS XRT only if + CNS disease) |
| Induction: 500-1000 × 3 doses | Induction: 3000-8000 | Induction: None | Induction: None | ||||
| Consolidation: None | Consolidation: 3000 | Consolidation: 100-3000 × 4-5 doses | Consolidation: None | ||||
| Hoelzer et al55 | B-NHL 83 | 6 | Cytoreduction: 200 × 5 doses | Cytoreduction: none | Cytoreduction: none | Cytoreduction: none | |
| Treatment: 200 × 5 doses | Treatment: 500 | Treatment: 300 | CNS XRT, IT MTX (spinal XRT if + CNS disease) | ||||
| B-NHL 86 | 6 | Cytoreduction: 200 × 5 doses | Cytoreduction: none | Cytoreduction: none | Cytoreduction: none | ||
| Treatment: 200 × 5 doses | Treatment: 1500 | Treatment: 150 q 12 h × 8 doses | Treatment: 800 × 5 doses | CNS XRT, IT MTX, ARA-C, and DEX (spinal XRT if + CNS disease) | |||
| Todeschini et al63 | Modified POG 8617 | 6 | 300 q 12 h × 6 doses | 1000 | 3000 q 12 h × 4 doses | None | IT MTX and ARA-C |
| Magrath et al54,64 | CODOX-M/IVAC | Low risk: 3 CODOX-M | 800 × 1 dose and 200 × 4 doses | 6720 | None | None | IT MTX & ARA-C (CNS XRT only if + CNS disease) |
| High risk: 4 CODOX-M/IVAC | 800 × 1 dose and 200 × 4 doses | 6720 | 2000 q 12 h × 4 doses | 1500 × 5 doses | IT MTX & ARA-C (CNS XRT only if + CNS disease) | ||
| Thomas et al56 | Hyper-CVAD | 8 | 300 q 12 h × 6 doses for 4 cycles | 1000 for 4 cycles | 3000 q 12 h × 4 doses for 4 cycles | None | IT MTX and ARA-C (CNS XRT only if + CNS disease) |
| Lee et al67 | CALGB 9251 | 6 | Cytoreduction: 200 × 5 doses | 1500 | 150 × 2 doses | 800 × 5 doses | IT MTX, ARA-C, HC, and CNS XRT |
| Treatment: 200 × 5 doses |
Note that the reported regimens also contain several chemotherapeutic agents, including doxorubicin, vincristine, dexamethasone, or prednisone, and others not reported in this table. CNS XRT indicates whole-brain irradiation; BM, bone marrow; IT, intrathecal; MTX, methotrexate, ARA-C, cytarabine; HC, hydrocortisone; DEX, dexamethasone; PRED, prednisolone.
All chemotherapy doses are total doses per cycle unless otherwise noted.
Duration was in months.